Our top pick for
Long-term investors
Cerecor Inc is a biotechnology business based in the US. Cerecor shares (CERC) are listed on the NASDAQ and all prices are listed in US Dollars. Cerecor employs 30 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Cerecor
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CERC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Cerecor stock price (NASDAQ: CERC)
Use our graph to track the performance of CERC stocks over time.Cerecor shares at a glance
Information last updated 2021-12-26.
| 52-week range | $2.03 - $4.50 |
|---|---|
| 50-day moving average | $2.88 |
| 200-day moving average | $3.01 |
| Wall St. target price | $6.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.87 |
Buy Cerecor shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cerecor stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cerecor price performance over time
Historical closes compared with the close of $N/A from 2021-11-26
| 1 week (2022-01-18) | N/A |
|---|---|
| 1 month (2021-12-25) | N/A |
| 3 months (2021-10-25) | N/A |
| 6 months (2021-07-29) | -100.00% |
| 1 year (2021-01-29) | -100.00% |
|---|---|
| 2 years (2020-01-29) | -100.00% |
| 3 years (2019-01-29) | -100.00% |
| 5 years (2017-01-27) | -100.00% |
Cerecor financials
| Revenue TTM | $6.4 million |
|---|---|
| Gross profit TTM | $-18,536,584 |
| Return on assets TTM | -72.52% |
| Return on equity TTM | -213.81% |
| Profit margin | 0% |
| Book value | $0.23 |
| Market capitalisation | $285 million |
TTM: trailing 12 months
Cerecor share dividends
We're not expecting Cerecor to pay a dividend over the next 12 months.
Cerecor share price volatility
Over the last 12 months, Cerecor's shares have ranged in value from as little as $2.03 up to $4.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerecor's is 1.4406. This would suggest that Cerecor's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cerecor overview
Cerecor Inc. , a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation.
Cerecor in the news
Frequently asked questions
What percentage of Cerecor is owned by insiders or institutions?Currently 0.79% of Cerecor shares are held by insiders and 70.39% by institutions. How many people work for Cerecor?
Latest data suggests 30 work at Cerecor. When does the fiscal year end for Cerecor?
Cerecor's fiscal year ends in December. Where is Cerecor based?
Cerecor's address is: 540 Gaither Road, Rockville, MD, United States, 20850 What is Cerecor's ISIN number?
Cerecor's international securities identification number is: US05338F1084 What is Cerecor's CUSIP number?
Cerecor's Committee on Uniform Securities Identification Procedures number is: 15671L109
More guides on Finder
-
Cathie Wood’s ARK analysts predict Bitcoin at $1 million each by 2030
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
-
Lido Staking
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
-
Stocks are dropping; 3 rules for buying on the dip
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
-
The crypto market has lost $1.5 trillion in value — time to buy?
The crypto market wiped out $1.5 trillion in value in just three months.
-
Bitcoin tumbles past $40,000, altcoins follow
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
-
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
-
Walmart dives deep into the metaverse with crypto and NFTs
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
-
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
-
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
-
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Ask an Expert